Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Athena Neurosciences Inc.

(ATHN)

Douglas Lind of Lind & Co. began coverage of ATHN with a "strong buy" and a one-year

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE